Chris Byrne, United Kingdom

University of Southampton, UK Nutrition and Metabolism, Faculty of Medicine
Professor Byrne trained as a clinical scientist in the UK and US; at Cardiff, Cambridge and Stanford Universities undertaking a PhD studying liver lipid metabolism at Cambridge University. Prof Byrne is Chair of Endocrinology & Metabolism at the University of Southampton and was inaugural Director of the Wellcome Trust Clinical Research Facility at University Hospital Southampton. Prof Byrne is a Metabolic Physician, with particular expertise in dyslipidaemias, metabolic liver disease and type 2 diabetes; and is currently Principal Investigator within the National Institute for Health Research Southampton Biomedical Research Centre. Prof Byrne’s research focusses on different aspects of NAFLD: including aetiology, pathogenesis, consequences and treatment. Prof Byrne has published >350 publications related to metabolic syndrome and NAFLD and was a recipient of the Dorothy Hodgkin prize for research excellence related to diabetes. In 2021, Prof Byrne was recognised by Expertscape as “World Expert in Fatty Liver” being placed in the top 0.1% of scholars writing about ‘fatty liver’ in the world over the last 10 years. Prof Byrne was the UK expert Diabetologist advisor to the National Institute for Health and Care Excellence (NICE) NAFLD Guidelines.

Presenter of 1 Presentation

PARALLEL SESSION

NAFLD/NASH in metabolic syndrome and early type 2 diabetes

Abstract

Abstract Body

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a metabolic liver disease that is strongly associated with obesity, type 2 diabetes (T2DM) and other metabolic and vascular risk factors. It is now established that NAFLD is a multisystem disease with consequences beyond the liver. NAFLD increases risk of many extra-hepatic diseases such as cardiovascular disease (CVD), chronic kidney disease (CKD) and certain cancers. NAFLD encompasses a spectrum of lipid-associated liver disease and in affected individuals NAFLD may progress from simple steatosis to steatohepatitis, liver fibrosis and cirrhosis. This presentation will discuss the relationships between NAFLD and type 2 diabetes that form part of a vicious cycle of spiralling and worsening metabolic disease. Not only does NAFLD increase risk of developing diabetes with insulin resistance and poor glycaemic control, but development of diabetes further increases risk of worsening liver disease, liver fibrosis and hepatocellular carcinoma. Relationships between NAFLD and cardiovascular disease and the modifying influence on cardiovascular disease of certain genotypes known to increase severity of liver disease will also be discussed.

Hide